PART I . Overview Our Business We are a cell therapy company focused on immunotherapy. Since our inception, we have been involved with the development of proprietary immune system management technology (Cell Source technology) licensed from Yeda Research & Development Company Limited (Yeda), the commercial arm of the Weizmann Institute of Science (Weizmann Institute) in Israel. The current focus of our Research and Development efforts is at the University of Texas MD Anderson Cancer Center (MD A...
Q2 FY2026 — expected 2026-07-22
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2024-06-24 | 2023-12-31 | 0001493152-24-024903 | EDGAR | 78K words |
| 2023-08-08 | 2022-12-31 | 0001493152-23-027069 | EDGAR | — |
| 2022-04-15 | 2021-12-31 | 0001493152-22-010133 | EDGAR | — |
| 2021-04-15 | 2020-12-31 | 0001640334-21-000923 | EDGAR | — |
| 2020-03-30 | 2019-12-31 | 0001640334-20-000672 | EDGAR | — |
| 2019-04-01 | 2018-12-31 | 0001165527-19-000034 | EDGAR | — |
| 2018-07-25 | 2017-12-31 | 0001165527-18-000154 | EDGAR | — |
| 2016-04-14 | 2015-12-31 | 0001165527-16-000733 | EDGAR | — |
| 2015-03-13 | 2014-12-31 | 0001144204-15-015954 | EDGAR | — |
| 2014-03-25 | 2013-12-31 | 0001165527-14-000161 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2024-11-14 | 2024-09-30 | 0001493152-24-045964 | EDGAR | 23K words |
| 2024-08-19 | 2024-06-30 | 0001493152-24-033055 | EDGAR | — |
| 2024-07-29 | 2024-03-31 | 0001493152-24-029448 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001493152-23-040079 | EDGAR | — |
| 2023-09-19 | 2023-06-30 | 0001493152-23-033011 | EDGAR | — |
| 2023-08-23 | 2023-03-31 | 0001493152-23-029915 | EDGAR | — |
| 2022-12-08 | 2022-09-30 | 0001493152-22-034876 | EDGAR | — |
| 2022-12-02 | 2022-06-30 | 0001493152-22-034255 | EDGAR | — |
| 2022-11-02 | 2022-03-31 | 0001493152-22-030233 | EDGAR | — |
| 2021-11-15 | 2021-09-30 | 0001493152-21-028675 | EDGAR | — |
| 2021-08-12 | 2021-06-30 | 0001493152-21-019491 | EDGAR | — |
| 2021-05-17 | 2021-03-31 | 0001493152-21-011971 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2025-06-27 | 0001641172-25-016833 | EDGAR | 1K words |
| 2024-04-09 | 0001493152-24-014035 | EDGAR | — |
| 2022-07-21 | 0001493152-22-019997 | EDGAR | — |
| 2022-05-06 | 0001493152-22-012387 | EDGAR | — |
| 2022-03-11 | 0001493152-22-006672 | EDGAR | — |
| 2021-04-02 | 0001640334-21-000755 | EDGAR | — |
| 2019-04-19 | 0001165527-19-000053 | EDGAR | — |
| 2015-11-16 | 0001165527-15-000545 | EDGAR | — |
| 2015-11-05 | 0001165527-15-000524 | EDGAR | — |
| 2015-08-19 | 0001165527-15-000418 | EDGAR | — |
75 total filings indexed. 43 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001569340 |
| Ticker | CLCS |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report